Safety and Performance Evaluation of the SAVA Continuous Glucose Monitor for Effective Glucose Detection

Inclusion Criteria: * The participant is willing and able to give informed consent to participate in the study. * The participant is at least 18 years of age at the time of enrolment. * The participant has a clinical diagnosis of Type 1 diabetes, with 7% \< HbA1C \< 10% within the last 6 months, for a minimum of 6 months duration prior to enrolment, as determined by a medical record by an individual qualified to make a medical diagnosis, and is using insulin (either by an insulin pump, subcutaneous injections, and/or inhaled insulin) for at least 6 months prior to enrolment. * If participant is using noninsulin glucose-lowering medications (such as SGLT2I Inhibitor, Metformin, or other), dose has been stable for at least 2 weeks prior to screening. * The participant body weight is at least 110 pounds, in accordance with U.S. Department of Health and Human Services guidance for blood collection. * The participant has adequate venous access as assessed by an investigator or appropriate centre staff. * The participant is available to attend all three up to 8-hour, clinically supervised, in-clinic sessions and to have multiple venous and capillary blood samples collected. * The participant agrees to not consume Vitamin C for the duration of the study. * The participant is prepared to record details related to their participation (e.g. meals, finger prick times, device incidents, comfort) daily. * The participant is prepared to wear up to three blinded investigational devices, an…